Retinoic acid receptor-b (RARb) and signal transducer and activator of transcription 1 (STAT1) are important mediators of the antiproliferative and apoptotic actions of retinoids and cytokines/growth factors, respectively. Expression of both RARb and STAT1 is lost in most breast cancer cell lines but it can be induced by retinoids in estrogen receptor-positive cells. We investigated a possible functional connection between these two mediators and present evidence supporting RARb as a tumor suppressor. First, by using dierent receptor-selective retinoids, we demonstrated that RARb induction in MCF-7 cells by all-trans-retinoic acid (atRA) was associated with the activation of STAT1 gene transcription. The direct involvement of RARb in atRA-induced STAT1 gene activation was further demonstrated by showing that transfection with an anti-sense RARb construct blocked atRA-induced STAT1 expression in MCF-7 cells whereas introduction of a sense-RARb construct resulted in STAT1 induction by atRA in MDA-MB 231 cells. In addition, we showed that STAT1 was phosphorylated/activated under atRA treatment of MCF-7 cells; this process required the involvement of RARb and protein synthesis. STAT1 phosphorylation/ activation was accompanied by increased tyrosine kinase activity that was not due to the activation of JAK1, JAK2 or Tyk 2, suggesting the possible involvement of an unidenti®ed tyrosine kinase.
Introduction
Retinoic acid receptor-b (RARb) and signal transducer and activator of transcription 1 (STAT1) mediate, respectively, the antiproliferative and apoptotic actions of retinoids (Mangelsdorf et al., 1994; Seewaldt et al., 1995; Bromberg et al., 1996; Si et al., 1996; Zhang et al., 1996) and cytokines/growth factors such as interferons (IFNs) (Chin et al., 1996; Gianni et al., 1997; Kumar et al., 1997; Sun et al., 1998) . Both of these mediators are expressed in normal human tissues such as the mammary epithelium (Darnell et al., 1994; Widschwendter et al., 1997) . However, in many tumors or tumor cells, the expression of both RARb and STAT1 is lost. For example, RARb expression is not detected in the majority of breast cancer cells (Swisshelm et al., 1994; Seewaldt et al., 1995) and in breast cancer (Widschwendter et al., 1997) , or in human lung cancer (Gerbert et al., 1991; Houle et al., 1991) and human oral and epidermal squamous cell lines (Houle et al., 1991) . Similarly, STAT1 is not expressed in breast cancer cells (Kolla et al., 1996) , human melanoma cells (Wong et al., 1997) , mutant human ®broblast U3A and U3X cells (Chin et al., 1996) , myeloid leukemia cells (Matikainen et al., 1997) , and T-cell lymphoma cells (Sun et al., 1998) . Antiproliferative agents such as retinoic acid (RA) are able to induce the expression of both RARb and STAT1 in certain malignancies including estrogen receptorpositive breast cancer cells (Seewaldt et al., 1995; Kolla et al., 1996) , myeloid leukemia cells (Matikainen et al., 1997) and acute promyelocytic leukemia cells (Gianni et al., 1997) . These observations suggest that (1) both RARb and STAT1 are tumor suppressors and lack of their expression may be involved in tumorigenesis; and (2) there may be a functional connection between RARb and STAT1 such that loss of RARb expression might result in loss of STAT1 expression. We report here that induction of STAT1 expression in both MCF-7 and MDA-MB 231 breast cancer cells by atRA is mediated by RARb; atRA may also exert IFN-like actions by phosphorylating STAT1 in MCF-7 cells, possibly through the induction of an unknown tyrosine kinase.
Results

STAT1 expression is induced by atRA in a dose-and time-dependent fashion in MCF-7 cells
To test the eects of atRA on the expression of STAT1, MCF-7 cells were grown in the presence of 0, 10 710 , 10
79
, 10
78
, 10 77 or 10 76 M of atRA for 96 h and STAT1 protein expression was analysed. MCF-7 cells did not express STAT1 protein in the absence of atRA but the expression was induced by atRA in a dosedependent fashion (Figure 1a ). Both STAT1 protein ( Figure 1b ) and mRNA levels ( Figure 1c ) increased when MCF-7 cells were incubated with atRA for increasing lengths of time.
atRA activates STAT1 gene transcription, and RAR rather than RXR signals this process Because studies with neuroblastoma cells (Higuchi et al., 1991) and breast cancer cells (Langenfeld et al., 1997) have shown that RA is able to regulate gene expression at the post-transcriptional level, we asked whether atRA directly activates the transcription of the STAT1 gene and via which retinoid receptor. MCF-7 cells were incubated with 10 76 M of either atRA, the RAR-speci®c agonist Ro 13-7410 or the RXR-speci®c agonist Ro 25-7386. Only atRA and the RAR-speci®c agonist Ro 13-7410 activated STAT1 gene transcription (Figure 2a ), indicating that RAR:RXR but not RXR:RXR is involved in transducing the atRA signal. Parallel experiments (Figure 2b ) showed that STAT1 protein was only induced by atRA and Ro 13-7410, the RAR-speci®c agonist.
To further verify the ability of the synthetic retinoids to activate retinoid receptors, a luciferase reporter gene under the control of a DR5 element, the canonical retinoic acid response element (RARE) activated by RARs, was introduced into MCF-7 cells. Only Ro 13-7410, the RAR-speci®c agonist, activated the expression of luciferase gene at the same level as did atRA (Figure 2c ).
Induction of STAT1 by atRA is mediated by RARb in breast cancer cells; RARb induction by atRA depends on RARa
To investigate the hypothesis that RARb is mediating atRA-induced STAT1 expression, we ®rst evaluated the ability of atRA to induce the expression of RARb in MCF-7 cells. Figure 3 shows that, while RARa expression was similar in atRA treated-or untreated cells, RARb was evident only after atRA treatment. Next we hypothesized that RARa is the RAR subtype that mediates the induction of RARb by atRA, whereas RARb is the subtype that directly mediates the eects of retinoids, such as induction of STAT1 gene transcription. As documented in Figure 4a , the RARa-selective antagonist Ro 41-5253 blocked the induction of RARb expression. With decreasing concentrations of Ro 41-5253, RARb expression increased, indicating that this process is mediated by RARa. Paralleling the diminished expression of RARb, STAT1 expression was also abolished (Figure 4b ), suggesting that RARb may mediate the induction of STAT1 expression by atRA. To test the hypothesis that RARb directly mediates the expression of STAT1, RARb sense and antisense constructs were introduced into MCF-7 cells via expression vectors. As exempli®ed by the results for b5 (Figure 4c ), Ro 41-5253 was unable to block atRAinduced STAT1 expression in clones of RARb sense transfectants. In contrast, in RARb antisense transfectants, the induction of STAT1 expression by atRA was totally blocked (Figure 4d ).
To further establish the role of RARb in the signaling of atRA-induced STAT1 expression in breast cancer cells, sense RARb was introduced into an estrogen receptor-negative breast cancer cell line, MDA-MB 231, that has nondetectable levels of RARa and RARb in the presence or absence of atRA (data not shown). MDA-MB 231 cells do not express STAT1 and atRA was unable to induce its expression ( Figure   4e ). However, when RARb was introduced, STAT1 expression was induced by atRA, indicating that RARb expression alone was adequate to mediate the expression of STAT1. In contrast, another estrogen receptor-negative breast cancer cell line, BT-20, which expresses high levels of RARa but is unable to express RARb in the presence of atRA (data not shown; also see Swisshelm et al., 1994; Zhang et al., 1996) , was unable to express STAT1 in the presence of atRA, indicating that RARa alone is not enough for mediating the induction of STAT1 by atRA.
atRA induces not only STAT1 expression but also STAT1 phosphorylation
We next investigated whether atRA-induced STAT1 protein could be activated by cytokines such as IFNs. No protein/DNA complexes were detected in cells grown in the absence of atRA, even after IFNg was added ( Figure 5a ). When MCF-7 cells were grown in the presence of atRA and IFNg was then added, STAT1 protein/DNA complexes were strongly induced. Surprisingly, atRA alone also induced the formation of protein/DNA complexes, suggesting that atRA may also induce the phosphorylation of STAT1.
To examine the possibility of STAT1 phosphorylation by atRA, MCF-7 cells were grown in the presence of atRA followed by immunoprecipitation with antibodies against STAT1 and Western blotting using antibodies against phosphotyrosine ( Figure 5b , upper panel). Tyrosine-phosphoprotein was detected even in cells treated with atRA alone, although the level of 76 M of atRA for 96 h. STAT1 expression was measured by Western blot analysis. Three dierent clones (As-b4, As-b6 and As-b9) of transfectants were analysed. (e) Total protein was prepared from MDA-MB 231 cells that had been transfected with an RARb sense expression vector and treated with 10 76 M of atRA for 96 h. STAT1 expression was measured by Western blot analysis. RARb sense transfectants derived from three dierent clones (b4, b5 and b7) were analysed 76 M of atRA for 72 h and 500 units/ml of IFN g for 30 min and analysed by electrophoretic mobility shift assays. The binding speci®city of DNA and STAT1 dimers was veri®ed by using rabbit polyclonal antibodies against STAT1 and rabbit polyclonal antibodies against RARa. (b) MCF-7 cells were grown in the presence (+) or absence (7) of 10 76 M of atRA for 72 h and IFN g for 30 min. Immunoprecipitations were performed with rabbit polyclonal antibodies against human STAT1, followed by Western blot analysis using antibodies against phosphotyrosine (upper panel) or STAT1 (lower panel) phosphorylation was lower than that induced by atRA plus IFNg. This corresponds well to the pattern of protein/DNA complexes shown in Figure 5a and indicates that atRA induces not only STAT1 expression but also its phosphorylation.
Activation of STAT1 by atRA requires de novo protein synthesis and RARb involvement
We wanted to exclude the possibility that an exogenous peptide(s) from the culture medium was responsible for STAT1 phosphorylation via binding to cell surface receptors. After 24 h of incubation in serum-containing medium, MCF-7 cells were switched to serum-free medium for another 24 h followed by treatment with 0 or 10 76 M of atRA for 48 h. Immunoprecipitation experiments (Figure 6a) showed that STAT1 was phosphorylated even in MCF-7 cells cultured in serum-free medium, ruling out the possibility that STAT1 was phosphorylated by exogenous peptide(s) present in the serum.
atRA-induced STAT1 phosphorylation could result from endogenously-induced peptide activator(s), such as IFNs. To examine this possibility, we ®rst investigated whether atRA-induced STAT1 phosphorylation requires protein synthesis. STAT1 expression was introduced into MCF-7 cells via the expression vector. Transfectants were treated with 10 76 M of atRA for various times, and immunoprecipitations were performed to analyse the kinetics of STAT1 phosphorylation. STAT1 phosphorylation was not detectable until 24 h after atRA treatment (Figure 6b , upper panel), although STAT1 protein was expressed at all times tested (Figure 6b , lower panel), suggesting that protein synthesis may be required for atRA-induced STAT1 phosphorylation.
To directly examine the requirement for protein synthesis in atRA-induced STAT1 phosphorylation, STAT1-transfected MCF-7 cells were pretreated with Figure 6 Activation of STAT1 by atRA requires de novo protein synthesis and RARb involvement. (a) atRA-induced STAT1 phosphorylation is not due to exogenous tyrosine kinase activators in the cell culture medium. MCF-7 cells were grown in serum-containing medium for 24 h, washed with PBS and switched to serum-free medium supplemented with 2 mg/ml ®bronectin and 2 mg/ml transferrin for another 24 h followed by treatment with 0 or 10 76 M of atRA for 48 h. Cells were then harvested and cell lysates were prepared followed by immunoprecipitation with rabbit polyclonal antibodies against human STAT1 and Western blotting using antibodies against phosphotyrosine. Immunoprecipitation experiments showed (Figure 6c ) that STAT1 phosphorylation was blocked when de novo protein synthesis was blocked by cycloheximide, supporting the idea that atRA-induced STAT1 phosphorylation requires protein synthesis. If a protein is synthesized during the atRA-induced STAT1 phosphorylation, this process most likely is mediated by retinoic acid receptors. We hypothesized that RARb is most likely to be the receptor subtype involved because of its critical roles in transducing retinoid signals in breast cancer cells. To test this hypothesis, we established doubly-transfected MCF-7 cell clones that expressed both STAT1 and antisense RARb. Similar experiments to those shown in Figure  6b were performed. However in this case, atRA did not phosphorylate STAT1, even at 48 h (Figure 6d , upper panel), indicating that RARb mediates the atRAinduced STAT1 phosphorylation. Taken together, these experiments suggest that atRA-induced phosphorylation of STAT1 resulted from RARb-mediated protein synthesis. Under similar conditions, cycloheximide inhibited 490% of protein synthesis in MCF-7 cells (Geier et al., 1992) . As assayed by trypan blue dye exclusion in our experiments, viability did not dier between control and experimental cells (data not shown). As shown in Figure 6c (lower panel), we also veri®ed that the ability of cycloheximide to block induction of a possible STAT1 activator was not due to a generalized decrease in transcription.
Possible involvement of an unidenti®ed tyrosine kinase in atRA-induced STAT1 phosphorylation
We reasoned that the newly synthesized protein(s) that resulted in STAT1 phosphorylation in response to atRA could be: (1) a new peptide activator capable of activating a known tyrosine kinase(s), (2) an unknown tyrosine kinase activated by an existing peptide activator, or (3) both. The known protein tyrosine kinases capable of STAT1 activation in response to extracellular signals are JAK1, JAK2 and Tyk 2 (Schindler and Darnell, 1995) . If STAT1 phosphorylation in response to atRA was due to an induced peptide activator, we would expect that at least one of the known kinases was activated. When we investigated this in MCF-7 cells, no phosphorylated JAK1, JAK2 or Tyk 2 was detected (Figure 7a ). In addition, MCF-7 cells were growth in the presence of 10 76 M atRA for 0, 24, 48 or 72 h and assayed for the expression of JAK1, JAK2 and Tyk 2. As shown in Figure 7b , all three tyrosine kinases were expressed in MCF-7 cells and their expression appeared not to be subject to regulation by atRA. These results do not support the idea that atRA-induced STAT1 phosphorylation resulted from induction of the synthesis of a kinase activator. To rule out the possibility that an atRAinduced activator in the medium caused STAT1 phosphorylation, MCF-7 cells were cultured with serum-free conditioned medium in the presence of 10 76 M of atRA for 48 h. Conditioned medium was applied to STAT1-transfected MCF-7 cell cultures grown in the conditioned medium without atRA for 0.5, 2, 5 or 10 h. The added medium did not cause STAT1 phosphorylation at any time tested (Figure 8 ), suggesting that it did not contain secreted STAT1 activators and that atRA-induced STAT1 phosphorylation is not due to the induction of activator(s).
Knowing that protein synthesis is required for STAT1 phosphorylation by atRA but that a kinase activator does not seem to be the protein product, we speculate that an unknown protein tyrosine kinase is induced by atRA, leading to phosphorylation of STAT. To support this idea, we measured tyrosine kinase activity in MCF-7 cells treated with atRA. JAK1, JAK2 and Tyk 2 were excluded from these cell lysates by immunodepletion with antibodies ( Figure   Figure 8 Tyrosine kinase activators were not secreted into the medium. MCF-7 cells were cultured in serum-free conditioned medium in the presence of 10 76 M of atRA for 48 h. Conditioned medium was then collected aseptically and applied to STAT1-transfected MCF-7 cell cultures for 0.5 h (lane 1), 2 h (lane 2), 5 h (lane 3) or 10 h (lane 4). Cell lysates were prepared followed by immunoprecipitation for analysing STAT1 phosphorylation using PY20 (upper panel). As a control, STAT1 phosphorylation was also measured in cell lysates from cell cultures that had been grown in serum-free conditioned medium (lane 5) and from cell cultures to which conditioned medium plus 500 units/ml of IFNg was added for 0.5 h. The lower panel shows that STAT1 protein was present in all experimental conditions 9b). As shown in Figure 9a , atRA treatment of MCF-7 cells was associated with a dose-dependent increase in tyrosine kinase activity, which, we propose, is due to an unidenti®ed tyrosine kinase.
Discussion
It is well accepted that estrogen receptor-positive breast cancer cell lines respond to the growth inhibitory eects of retinoids much better than do estrogen receptor-negative breast cancer cell lines. It appears that this dierence parallels variations in RARa expression. Some studies suggest that RARa is the key player in the growth inhibitory action of retinoids in breast cancer cells (Sheikh et al., 1994; Fitzgerald et al., 1997) , whereas others have identi®ed RARb as the mediator of growth inhibition in breast cancer cells (Seewaldt et al., 1995; Liu et al., 1997) and other tumor cells (Houle et al., 1991; Berard et al., 1996; Si et al., 1996) . Another RAR subtype, RARg, that is generally believed to function in skin (Mangelsdorf et al., 1994) , is also expressed in MCF-7 and MDA-MB 231 cell lines (Swisshelm et al., 1994; Liu et al., 1997) but its role in mammary gland has not been determined. Thus our attention was focused on RARa and RARb. We demonstrated here that it is RARb that directly mediates the activation of STAT1 gene transcription. That is, loss of RARb would result in no STAT1 induction by retinoids, loss of growth regulation and tumor development.
Interestingly, we showed that STAT1 was phosphorylated/activated after atRA treatment in MCF-7 cells. STAT1 phosphorylation requires protein synthesis and RARb involvement. The possibility that an exogenous tyrosine kinase activator in the culture medium was responsible for STAT1 phosphorylation was eliminated in experiments using serum-free conditioned medium. These studies showed that all three known tyrosine kinases, JAK1, JAK2 and Tyk 2, which are known kinases responsible for STAT1 phosphorylation, were not activated after treatment with atRA. Furthermore, it is not likely that an endogenously-induced tyrosine activator was responsible for STAT1 phosphorylation, because the cell culture medium collected after treatment with atRA was not able to phosphorylate STAT1 in STAT1-transfected MCF-7 cells. These results, together with our demonstration of an atRA dose-dependent increase in non-JAK1, JAK2 and Tyk 2 tyrosine kinase activity in MCF-7 cells, suggest the involvement of an unknown tyrosine kinase in the atRA-induced phosphorylation of STAT1. An increased tyrosine kinase activity after treatment with retinoids has also been reported in NB4 cells, an acute promyelocytic leukemia-derived cell line (Gianni et al., 1995) . The con®rmation of the induction of an unknown tyrosine kinase by retinoids needs protein puri®cation and cDNA cloning of such a kinase.
STAT1 phosphorylation induced by atRA treatment seemed to be weaker and slower than that induced by IFNg. If there is a tyrosine kinase involved in this process, it is possible that STAT1 is not a primary and direct target of this kinase. Ultimately, it will be interesting to identify the biological signi®cance of STAT1 phosphorylation/activation by atRA. A variety of downstream eectors of STAT1 activation have been reported . We have studied one of these eectors, pkr (Shang et al., 1998) , which encodes for a double-stranded RNAdependent protein kinase (PKR) and has been implicated in tumor growth and cell dierentiation . When we examined PKR expression after atRA treatment and STAT1 phosphorylation in response to this treatment, both messenger RNA and protein of PKR were undetectable. We have not investigated the activation of other genes after atRA-induced STAT1 activation, but such studies are warranted.
By demonstrating RARb-mediated induction of STAT1, our experiments underscore the importance of RARb both in the normal growth regulation of the mammary gland and in breast cancer carcinogenesis. Further studies are needed to characterize the unidenti®ed kinase and to de®ne the biological signi®cance of STAT1 phosphorylation.
Materials and methods
Cell cultures, retinoids, cytokines and reagents
Breast carcinoma cell lines (MCF-7, MDA-MB 231 and BT-20; American Type Culture Collection, Manassas, VA, USA) were grown in phenol red-free Eagle's minimal essential medium (Sigma, St. Louis, MO, USA) supplemented with 5% charcoal-stripped calf serum (Sigma).
atRA, IFNa, IFNg, ®bronectin, transferrin and cycloheximide were purchased from Sigma. The RAR-speci®c agonist Ro 13-7410, the RXR-speci®c agonist Ro 25-7386 and the RARa -selective antagonist Ro 41-5253 were donated by Homann-La Roche (Basel, Switzerland).
Transient transfection
Ten mg of DR5-tk-Luc (a luciferase reporter gene construct controlled by a retinoic acid response element; provided by Dr RM Evans, Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA) was co-transfected into MCF-7 cells with 2 mg of b-galactosidase expression vector (pCMVb; Clontech, Palo Alto, CA, USA) using Lipofectin reagent (Gibco BRL, Bethesda, MD, USA). Transfection eciency was normalized to b-galactosidase activity.
Stable transfection
Plasmid constructs for stable transfection experiments were pRC/CMV-RARb, pRC/CMV-antisense RARb (generous gifts from Dr X-K. Zhang, La Jolla Cancer Research Center, La Jolla, CA, USA) and pRC/CMV-STAT1 (provided by Dr JE Darnell, Jr, Laboratory of Molecular Cell Biology, The Rockefeller University, New York, NY, USA). MCF-7 cells grown to 50% con¯uence were washed with serum-free growth medium. Two mg of either empty vector or construct was mixed with Lipofectin reagent and added to cells for 5 h. Selection was initiated with 400 mg/ml of G418 (Gibco BRL) on the third day and continued for 17 ± 21 days until drug-resistant colonies emerged. Single colonies were cloned and assayed for the expression of the inserted genes by Northern blotting.
Northern blot analysis
Hybridization was carried out using the following probes: T 4 polynucleotide kinase-labeled 40-mer antisense RARa, RARb or b-actin DNA (Oncogene Research Products, Cambridge, MA, USA), or random primer-labeled *882 bp XhoI and EcoRI fragment of human wild-type STAT1 cDNA. The results were analysed with a phosphorimager (Bio-Rad, Hercules, CA, USA).
Nuclear run-on assay MCF-7 cell nuclei were incubated with 10 mCi [a-32 P]UTP (ICN Pharmaceuticals, Inc., Irvine, CA, USA). Newly transcribed RNA was hybridized to the XhoI and EcoRI fragment of STAT1 cDNA (see above) that was immobilized on nylon membranes. The results were analysed using the phosphorimager.
Electrophoretic mobility shift assay
The oligonucleotides used in experiments for STAT1 binding were GAS gel shift oligonucleotides (5'-CAT GTT ATG CAT ATT CCT GTA AGT G-3'; Santa Cruz Biotech Inc., Santa Cruz, CA, USA). Ten mg of MCF-7 cell nuclear extract was mixed with 10 000 c.p.m. of these oligonucleotides labeled with [g-32 P]ATP (ICN Pharmaceuticals, Inc., Irvine, CA, USA), 2 mg poly(dI-dC) : poly(dI-dC) and 300 mg/ml BSA, and loaded onto a 4% polyacrylamide gel. The gel was then dried and exposed to X-ray ®lm. For con®rming the oligonucleotide-bound protein, rabbit polyclonal antibodies against STAT1 (Santa Cruz Biotech) were used as speci®c antibodies and rabbit polyclonal antibodies against RARa (Santa Cruz Biotech) were used as nonspeci®c antibodies.
Immunoprecipitation
Cell lysates were pre-cleaned using normal rabbit serum and immunoprecipitation was performed for 2 h using the rabbit polyclonal antibodies against STAT1 mentioned above. Protein A agarose (Bio-Rad) then was added and lysates were left overnight. Immunoprecipitates were boiled for 3 min in SDS gel loading buer and were used in a Western blotting procedure. Tyrosine phosphorylation of STAT1 protein was detected by using a mouse monoclonal antibody against phosphotyrosine (PY20) (Santa Cruz Biotech).
Immunodepletion
Cell lysates were incubated with rabbit polyclonal antibodies against JAK1, rabbit polyclonal antibodies against JAK2 or goat polyclonal antibodies against Tyk 2 (Santa Cruz Biotech) for 2 h followed by incubation with protein A agarose overnight. Supernatants were separated from immunoprecipitates by centrifugation and used for tyrosine kinase assay.
Tyrosine kinase assay
Tyrosine kinase activity assay was performed using a tyrosine kinase assay kit according to the manufacturer's instructions (Boehringer Mannheim Corp., Indianapolis, IN, USA) with a synthetic oligopeptide ± KVEKIGEGTYGVVYK ± corresponding to the amino acids 6 ± 20 of the cell division kinase p34 cdc2 as the substrate.
Western blot analysis
The following primary antibodies were used: rabbit polyclonal antibodies against STAT1, rabbit polyclonal antibodies against JAK1, rabbit polyclonal antibodies against JAK2 or goat polyclonal antibodies against Tyk 2 as described above. After adding appropriate secondary antibodies, the blots were developed using an ECL kit (Amersham, Arlington Heights, IL, USA). The results were analysed using EagleEye 1 and OnedScan software (Stratagene, La Jolla, CA, USA).
